JP2017210484A5 - - Google Patents

Download PDF

Info

Publication number
JP2017210484A5
JP2017210484A5 JP2017162282A JP2017162282A JP2017210484A5 JP 2017210484 A5 JP2017210484 A5 JP 2017210484A5 JP 2017162282 A JP2017162282 A JP 2017162282A JP 2017162282 A JP2017162282 A JP 2017162282A JP 2017210484 A5 JP2017210484 A5 JP 2017210484A5
Authority
JP
Japan
Prior art keywords
group
compound
cooh
hydrogen
oso
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017162282A
Other languages
English (en)
Japanese (ja)
Other versions
JP6417003B2 (ja
JP2017210484A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2017210484A publication Critical patent/JP2017210484A/ja
Publication of JP2017210484A5 publication Critical patent/JP2017210484A5/ja
Application granted granted Critical
Publication of JP6417003B2 publication Critical patent/JP6417003B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017162282A 2014-02-03 2017-08-25 化学療法剤としてのβ置換βアミノ酸および類似体 Active JP6417003B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461935246P 2014-02-03 2014-02-03
US61/935,246 2014-02-03

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016567477A Division JP6200603B2 (ja) 2014-02-03 2015-02-03 化学療法剤としてのβ置換βアミノ酸および類似体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018189332A Division JP2019023214A (ja) 2014-02-03 2018-10-04 化学療法剤としてのβ置換βアミノ酸および類似体

Publications (3)

Publication Number Publication Date
JP2017210484A JP2017210484A (ja) 2017-11-30
JP2017210484A5 true JP2017210484A5 (enExample) 2018-03-22
JP6417003B2 JP6417003B2 (ja) 2018-10-31

Family

ID=52589758

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016567477A Active JP6200603B2 (ja) 2014-02-03 2015-02-03 化学療法剤としてのβ置換βアミノ酸および類似体
JP2017162282A Active JP6417003B2 (ja) 2014-02-03 2017-08-25 化学療法剤としてのβ置換βアミノ酸および類似体
JP2018189332A Withdrawn JP2019023214A (ja) 2014-02-03 2018-10-04 化学療法剤としてのβ置換βアミノ酸および類似体

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016567477A Active JP6200603B2 (ja) 2014-02-03 2015-02-03 化学療法剤としてのβ置換βアミノ酸および類似体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018189332A Withdrawn JP2019023214A (ja) 2014-02-03 2018-10-04 化学療法剤としてのβ置換βアミノ酸および類似体

Country Status (16)

Country Link
US (5) US9394237B2 (enExample)
EP (1) EP3102195B1 (enExample)
JP (3) JP6200603B2 (enExample)
KR (1) KR101900584B1 (enExample)
CN (1) CN106163509B (enExample)
AU (2) AU2015210638B2 (enExample)
BR (1) BR112016017997A2 (enExample)
CA (1) CA2938571C (enExample)
DK (1) DK3102195T3 (enExample)
ES (1) ES2896882T3 (enExample)
IL (1) IL247099A0 (enExample)
MX (1) MX2016010095A (enExample)
NZ (1) NZ723940A (enExample)
SG (2) SG10201710436WA (enExample)
TW (1) TWI597260B (enExample)
WO (1) WO2015117147A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2896882T3 (es) 2014-02-03 2022-02-28 Quadriga Biosciences Inc Beta-aminoácidos beta sustituidos y análogos como agentes quimioterapéuticos
US20160346240A1 (en) * 2014-02-03 2016-12-01 Quadriga Biosciences, Inc. Methods of chemotherapy using chemotherapeutic agents based on beta-substituted beta-amino acids and analogs
CN106132406B (zh) 2014-02-03 2020-03-27 夸德里加生物科学公司 作为化疗剂的β-取代的γ-氨基酸和类似物
AR105592A1 (es) 2015-08-03 2017-10-18 Quadriga Biosciences Inc b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS
CN109174181B (zh) * 2018-08-10 2021-05-25 华东师范大学 一种负载双功能离子液体介孔聚合物的制备及其应用
TW202140440A (zh) * 2020-02-28 2021-11-01 美商克力歐普股份有限公司 Gpr40激動劑
WO2022147743A1 (en) * 2021-01-08 2022-07-14 Quadriga Biosciences, Inc. Pharmaceutical compositions of chemotherapeutic agents based on beta-substituted beta-amino acid derivatives
IL307258A (en) 2021-04-05 2023-11-01 Halia Therapeutics Inc NEK7 inhibitors
US12427124B1 (en) 2024-04-10 2025-09-30 Maxymune Therapeutics, Inc. Phenylalanine-based LAT1 inhibitors and uses thereof

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3235594A (en) 1962-04-02 1966-02-15 Frosst & Co Charles E N-acyl-alpha-amino acid amides
US3299104A (en) 1963-04-09 1967-01-17 Leo Ab Certain steroid nu-bis-(haloethyl)-carbamates
DK287977A (da) 1976-07-12 1978-01-13 Merck & Co Inc Fremgangsmade til fremstilling af 2-(3-(2-(thiazolyl-eller thiazolinyl)thio) phenyl)-alkan-(eller alken) syrer
US4339443A (en) 1978-09-22 1982-07-13 Fbc Limited Compounds and compositions
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US5015644A (en) 1987-06-02 1991-05-14 Warner-Lambert Company Antihyperlipidemic and antiatherosclerotic urea and carbamate compounds
FR2688499B1 (fr) * 1992-03-10 1994-05-06 Rhone Poulenc Rorer Sa Procede de preparation de la beta-phenylisoserine et de ses analogues.
US5602278A (en) 1994-10-20 1997-02-11 Kirkpatrick; Lynn N-oxides and derivatives of chlorambucil for treating hypoxic tumor cells
CA2207404C (en) 1994-12-13 2004-06-29 F. Hoffmann-La Roche Ag Imidazole derivatives as protein kinase inhibitors in particular egf-r tyrosine kinase
JP3163391B2 (ja) * 1995-03-07 2001-05-08 味の素株式会社 スチルベン誘導体及びそれを含有する制癌剤
TW334418B (en) * 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
US6172057B1 (en) 1997-02-27 2001-01-09 American Cyanamid Company N-Hydroxy-2-(alkyl, aryl, or heteroaryl sulfanyl, sulfinyl or sulfonyl)-3-substituted alkyl, aryl or heteroarylamides as matrix metalloproteinase inhibitors
US6306909B1 (en) * 1997-03-12 2001-10-23 Queen's University At Kingston Anti-epileptogenic agents
ES2227896T3 (es) 1997-12-16 2005-04-01 Warner-Lambert Company Llc Derivados de 1-aminometil-cicloalcanos sustituidos en 1 (=analogos de gabapentina), su preparacion y su uso en el tratamiento de trastornos neurologicos.
TWI244481B (en) 1998-12-23 2005-12-01 Pfizer 3-azabicyclo[3.1.0]hexane derivatives useful in therapy
GB0018528D0 (en) 2000-07-27 2000-09-13 Photocure Asa Compounds
GB0103857D0 (en) 2001-02-16 2001-04-04 Avecia Ltd Preparation of chloromandelic acid
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
WO2003018565A1 (en) 2001-08-29 2003-03-06 Chirologix Pharmaceuticals Inc. Method for synthesizing oxazinones
US20040087556A1 (en) 2002-11-06 2004-05-06 Lynn Kirkpatrick N-oxides and derivatives of melphalan for treating diseased states associated with hypoxia inducible factor
JP2004175692A (ja) 2002-11-25 2004-06-24 Fuso Pharmaceutical Industries Ltd 抗腫瘍剤
EP1572188A1 (en) 2002-12-13 2005-09-14 Warner-Lambert Company LLC Pregabalin derivatives for the treatment of fibromyalgia and other disorders
AU2004267100B2 (en) 2003-08-20 2010-10-07 Xenoport, Inc. Acyloxyalkyl carbamate prodrugs, methods of synthesis and use
JPWO2005044780A1 (ja) * 2003-11-10 2007-05-17 杏林製薬株式会社 アミノカルボン酸誘導体とその付加塩及びs1p受容体調節剤
EP1716115B1 (en) 2003-12-30 2013-02-27 XenoPort, Inc. Synthesis of acyloxyalkyl carbamate prodrugs and intermediates thereof
WO2005110416A2 (en) 2004-05-08 2005-11-24 Neurogen Corporation 4,5-disubstituted-2-aryl pyrimidines
US20060223866A1 (en) * 2004-08-13 2006-10-05 Praecis Pharmaceuticals, Inc. Methods and compositions for modulating sphingosine-1-phosphate (S1P) receptor activity
EA200700717A1 (ru) 2004-09-24 2007-10-26 Янссен Фармацевтика Н.В. Сульфонамиды
US20090221666A1 (en) * 2005-05-12 2009-09-03 Pettit George R Stilbene derivatives and methods of inhibiting cancer cell growth and microbial growth
JP2008540568A (ja) * 2005-05-12 2008-11-20 アテヌオン・リミテッド・ライアビリティ・カンパニー 抗血管形成化合物を用いた炎症性腸疾患の治療
CA2618513A1 (en) 2005-08-11 2007-02-22 Ariad Pharmaceuticals, Inc. Unsaturated heterocyclic derivatives
WO2007017511A2 (de) 2005-08-11 2007-02-15 Boehringer Ingelheim International Gmbh Verbindungen zur behandlung der alzheimer erkrankung
TWI328730B (en) 2006-06-16 2010-08-11 Ablerex Electronics Co Ltd Maximum power point tracking method and tracker thereof for a solar power system
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
US20080045534A1 (en) 2006-08-18 2008-02-21 Valeant Pharmaceuticals North America Derivatives of 1,3-diamino benzene as potassium channel modulators
EP1900729A1 (en) 2006-09-15 2008-03-19 Novartis AG Benzoxazoles and oxazolopyridines being useful as Janus kinases inhibitors
WO2008088690A2 (en) 2007-01-12 2008-07-24 Merck & Co., Inc. A process for preparing diazabicyclo[3.3.1] nonane compounds
GB0705656D0 (en) 2007-03-23 2007-05-02 Addex Pharmaceuticals Sa Novel compounds E1
US8168617B2 (en) 2007-09-07 2012-05-01 Xenoport, Inc. Complex pantoic acid ester neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use
EP2348857B1 (en) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
TWI468375B (zh) 2008-10-27 2015-01-11 Janssen Pharmaceutica Nv 製備經保護之l-丙胺酸衍生物之方法
BRPI1006116A2 (pt) 2009-01-19 2018-03-13 Abbott Lab "agentes indutores da apoptose para o tratamento de câncer e doenças imunes e autoimunes".
WO2010120370A2 (en) 2009-04-17 2010-10-21 Xenoport, Inc. Gamma-amino-butyric acid derivatives as gabab receptor ligands
EP2421835A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited N-pyrazolyl carboxamides as crac channel inhibitors
CN102030683B (zh) 2009-09-27 2013-07-31 浙江九洲药业股份有限公司 西他列汀中间体及其制备方法和用途
CA2805808A1 (en) 2010-07-23 2012-01-26 Connexios Life Sciences Pvt. Ltd. Agonists of gpr40
PL3196202T3 (pl) 2011-09-02 2019-09-30 Incyte Holdings Corporation Heterocykloaminy jako inhibitory pi3k
KR101352635B1 (ko) 2011-12-29 2014-01-20 연세대학교 산학협력단 신규 혈관누출 차단제
DK2746250T3 (en) 2012-12-21 2018-01-02 Abx Advanced Biochemical Compounds Gmbh Intermediates and Processes for Preparation of 18F-Labeled Amino Acids
US20150353542A1 (en) 2013-01-14 2015-12-10 Amgen Inc. Methods of using cell-cycle inhibitors to modulate one or more properties of a cell culture
ES2896882T3 (es) 2014-02-03 2022-02-28 Quadriga Biosciences Inc Beta-aminoácidos beta sustituidos y análogos como agentes quimioterapéuticos
AR105592A1 (es) * 2015-08-03 2017-10-18 Quadriga Biosciences Inc b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS

Similar Documents

Publication Publication Date Title
JP2017210484A5 (enExample)
JP2019034943A5 (enExample)
JP2006143746A5 (enExample)
JP2013079282A5 (enExample)
JP2018529687A5 (enExample)
JP2009543795A5 (enExample)
JP2010526146A5 (enExample)
JP2016534063A5 (enExample)
JP2013515752A5 (enExample)
JP2018534286A5 (enExample)
JP2010534246A5 (enExample)
CU23967B1 (es) Derivados de pirazin-2-carboxamida para tratar enfermedades mediadas por el bloqueo del canal de sodio epitelial
JP2011525192A5 (enExample)
JP2004536811A5 (enExample)
JP2020507589A5 (enExample)
JP2016514699A5 (enExample)
JP2009502829A5 (enExample)
JP2010520851A5 (enExample)
JP2019535723A5 (enExample)
JP2008520662A5 (enExample)
JP2019519593A5 (enExample)
JP2008546770A5 (enExample)
JP2010508310A5 (enExample)
RU2489433C9 (ru) Производное циклобутилпурина, агент, активирующий ангиогенез, агент, активирующий образование просвета, агент, активирующий рост нейронов, и лекарственное средство
CN111788197A (zh) 取代的二氨基杂环甲酰胺化合物及包含该化合物的组合物及其用途